Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function

Background The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Chest 2014-03, Vol.145 (3), p.579-585
Hauptverfasser: Schmidt, Shelley L., MD, Tayob, Nabihah, MS, Han, Meilan K., MD, Zappala, Christopher, MD, Kervitsky, Dolly, CRT, Murray, Susan, ScD, Wells, Athol U., MD, Brown, Kevin K., MD, FCCP, Martinez, Fernando J., MD, Flaherty, Kevin R., MD, FCCP
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 585
container_issue 3
container_start_page 579
container_title Chest
container_volume 145
creator Schmidt, Shelley L., MD
Tayob, Nabihah, MS
Han, Meilan K., MD
Zappala, Christopher, MD
Kervitsky, Dolly, CRT
Murray, Susan, ScD
Wells, Athol U., MD
Brown, Kevin K., MD, FCCP
Martinez, Fernando J., MD
Flaherty, Kevin R., MD, FCCP
description Background The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). Methods Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. Results During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P = .59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). Conclusions PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.
doi_str_mv 10.1378/chest.13-0844
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3941249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0012369215343713</els_id><sourcerecordid>1504451663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-ad3f6b5ccf17390cd4563abe775b27b93d696bd7e56cdcf0fb5dca5047f38f593</originalsourceid><addsrcrecordid>eNp1Uk1v1DAQtRAV3bYcuaIcuaTYGX9sLpXQwgJSJVZqe7Yce9K6JHaxk0r99zhsWxUkTjOjefNm9N4Q8o7RUwZq_dHeYJ5KWtM156_IirXAahAcXpMVpaypQbbNITnK-ZaWmrXyDTlseANszeiKXOwSOm8nH66r3TyMMZj0UG19l2L2ufrsM5qM1SbOqYRtimO1M3mqLhMGlysfXk7NoRDFcEIOejNkfPsYj8nV9svl5lt9_uPr982n89oKIafaOOhlJ6ztmYKWWseFBNOhUqJrVNeCk63snEIhrbM97TvhrBGUqx7WvWjhmJztee_mbkRnMUzJDPou-bGco6Px-u9O8Df6Ot5raDlr-ELw4ZEgxV9z0VGPPlscBhMwzlmzsowLJiUUaL2H2iJMTtg_r2FUL0boP0aUVC9GFPz7l7c9o5-ULwC1B2BR6N5j0tl6DLa4kdBO2kX_X-qzfybt4IO3ZviJD5hvi1WhyK6Zzo2m-mL5guUJmAAOigH8Bpcgrxo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504451663</pqid></control><display><type>article</type><title>Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Schmidt, Shelley L., MD ; Tayob, Nabihah, MS ; Han, Meilan K., MD ; Zappala, Christopher, MD ; Kervitsky, Dolly, CRT ; Murray, Susan, ScD ; Wells, Athol U., MD ; Brown, Kevin K., MD, FCCP ; Martinez, Fernando J., MD ; Flaherty, Kevin R., MD, FCCP</creator><creatorcontrib>Schmidt, Shelley L., MD ; Tayob, Nabihah, MS ; Han, Meilan K., MD ; Zappala, Christopher, MD ; Kervitsky, Dolly, CRT ; Murray, Susan, ScD ; Wells, Athol U., MD ; Brown, Kevin K., MD, FCCP ; Martinez, Fernando J., MD ; Flaherty, Kevin R., MD, FCCP</creatorcontrib><description>Background The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). Methods Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. Results During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P = .59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). Conclusions PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.</description><identifier>ISSN: 0012-3692</identifier><identifier>EISSN: 1931-3543</identifier><identifier>DOI: 10.1378/chest.13-0844</identifier><identifier>PMID: 24231810</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Disease Progression ; Female ; Follow-Up Studies ; Humans ; Idiopathic Pulmonary Fibrosis - diagnosis ; Idiopathic Pulmonary Fibrosis - mortality ; Idiopathic Pulmonary Fibrosis - physiopathology ; Male ; Middle Aged ; Original Research ; Predictive Value of Tests ; Prognosis ; Pulmonary/Respiratory ; Respiratory Function Tests ; Retrospective Studies ; Severity of Illness Index ; Survival Rate - trends ; Time Factors ; United States - epidemiology ; Vital Capacity - physiology</subject><ispartof>Chest, 2014-03, Vol.145 (3), p.579-585</ispartof><rights>The American College of Chest Physicians</rights><rights>2014 The American College of Chest Physicians</rights><rights>2014 American College of Chest Physicians 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c556t-ad3f6b5ccf17390cd4563abe775b27b93d696bd7e56cdcf0fb5dca5047f38f593</citedby><cites>FETCH-LOGICAL-c556t-ad3f6b5ccf17390cd4563abe775b27b93d696bd7e56cdcf0fb5dca5047f38f593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24231810$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Schmidt, Shelley L., MD</creatorcontrib><creatorcontrib>Tayob, Nabihah, MS</creatorcontrib><creatorcontrib>Han, Meilan K., MD</creatorcontrib><creatorcontrib>Zappala, Christopher, MD</creatorcontrib><creatorcontrib>Kervitsky, Dolly, CRT</creatorcontrib><creatorcontrib>Murray, Susan, ScD</creatorcontrib><creatorcontrib>Wells, Athol U., MD</creatorcontrib><creatorcontrib>Brown, Kevin K., MD, FCCP</creatorcontrib><creatorcontrib>Martinez, Fernando J., MD</creatorcontrib><creatorcontrib>Flaherty, Kevin R., MD, FCCP</creatorcontrib><title>Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function</title><title>Chest</title><addtitle>Chest</addtitle><description>Background The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). Methods Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. Results During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P = .59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). Conclusions PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.</description><subject>Disease Progression</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Idiopathic Pulmonary Fibrosis - diagnosis</subject><subject>Idiopathic Pulmonary Fibrosis - mortality</subject><subject>Idiopathic Pulmonary Fibrosis - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Research</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Pulmonary/Respiratory</subject><subject>Respiratory Function Tests</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Survival Rate - trends</subject><subject>Time Factors</subject><subject>United States - epidemiology</subject><subject>Vital Capacity - physiology</subject><issn>0012-3692</issn><issn>1931-3543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1Uk1v1DAQtRAV3bYcuaIcuaTYGX9sLpXQwgJSJVZqe7Yce9K6JHaxk0r99zhsWxUkTjOjefNm9N4Q8o7RUwZq_dHeYJ5KWtM156_IirXAahAcXpMVpaypQbbNITnK-ZaWmrXyDTlseANszeiKXOwSOm8nH66r3TyMMZj0UG19l2L2ufrsM5qM1SbOqYRtimO1M3mqLhMGlysfXk7NoRDFcEIOejNkfPsYj8nV9svl5lt9_uPr982n89oKIafaOOhlJ6ztmYKWWseFBNOhUqJrVNeCk63snEIhrbM97TvhrBGUqx7WvWjhmJztee_mbkRnMUzJDPou-bGco6Px-u9O8Df6Ot5raDlr-ELw4ZEgxV9z0VGPPlscBhMwzlmzsowLJiUUaL2H2iJMTtg_r2FUL0boP0aUVC9GFPz7l7c9o5-ULwC1B2BR6N5j0tl6DLa4kdBO2kX_X-qzfybt4IO3ZviJD5hvi1WhyK6Zzo2m-mL5guUJmAAOigH8Bpcgrxo</recordid><startdate>20140301</startdate><enddate>20140301</enddate><creator>Schmidt, Shelley L., MD</creator><creator>Tayob, Nabihah, MS</creator><creator>Han, Meilan K., MD</creator><creator>Zappala, Christopher, MD</creator><creator>Kervitsky, Dolly, CRT</creator><creator>Murray, Susan, ScD</creator><creator>Wells, Athol U., MD</creator><creator>Brown, Kevin K., MD, FCCP</creator><creator>Martinez, Fernando J., MD</creator><creator>Flaherty, Kevin R., MD, FCCP</creator><general>Elsevier Inc</general><general>American College of Chest Physicians</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140301</creationdate><title>Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function</title><author>Schmidt, Shelley L., MD ; Tayob, Nabihah, MS ; Han, Meilan K., MD ; Zappala, Christopher, MD ; Kervitsky, Dolly, CRT ; Murray, Susan, ScD ; Wells, Athol U., MD ; Brown, Kevin K., MD, FCCP ; Martinez, Fernando J., MD ; Flaherty, Kevin R., MD, FCCP</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-ad3f6b5ccf17390cd4563abe775b27b93d696bd7e56cdcf0fb5dca5047f38f593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Disease Progression</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Idiopathic Pulmonary Fibrosis - diagnosis</topic><topic>Idiopathic Pulmonary Fibrosis - mortality</topic><topic>Idiopathic Pulmonary Fibrosis - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Research</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Pulmonary/Respiratory</topic><topic>Respiratory Function Tests</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Survival Rate - trends</topic><topic>Time Factors</topic><topic>United States - epidemiology</topic><topic>Vital Capacity - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schmidt, Shelley L., MD</creatorcontrib><creatorcontrib>Tayob, Nabihah, MS</creatorcontrib><creatorcontrib>Han, Meilan K., MD</creatorcontrib><creatorcontrib>Zappala, Christopher, MD</creatorcontrib><creatorcontrib>Kervitsky, Dolly, CRT</creatorcontrib><creatorcontrib>Murray, Susan, ScD</creatorcontrib><creatorcontrib>Wells, Athol U., MD</creatorcontrib><creatorcontrib>Brown, Kevin K., MD, FCCP</creatorcontrib><creatorcontrib>Martinez, Fernando J., MD</creatorcontrib><creatorcontrib>Flaherty, Kevin R., MD, FCCP</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Chest</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schmidt, Shelley L., MD</au><au>Tayob, Nabihah, MS</au><au>Han, Meilan K., MD</au><au>Zappala, Christopher, MD</au><au>Kervitsky, Dolly, CRT</au><au>Murray, Susan, ScD</au><au>Wells, Athol U., MD</au><au>Brown, Kevin K., MD, FCCP</au><au>Martinez, Fernando J., MD</au><au>Flaherty, Kevin R., MD, FCCP</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function</atitle><jtitle>Chest</jtitle><addtitle>Chest</addtitle><date>2014-03-01</date><risdate>2014</risdate><volume>145</volume><issue>3</issue><spage>579</spage><epage>585</epage><pages>579-585</pages><issn>0012-3692</issn><eissn>1931-3543</eissn><abstract>Background The clinical course of idiopathic pulmonary fibrosis (IPF) is characterized by progressive decline in lung function and eventual mortality. We sought to determine if future declines in pulmonary function, mortality, or both can be predicted from prior trends in pulmonary function tests (PFTs). Methods Data from 1981 to 2008 on 4,431 PFTs and mortality were analyzed from 734 subjects with IPF. The Kaplan-Meier method was used for mortality analyses. Mixed models were used to describe longitudinal pulmonary function dynamics, since PFTs were observed at varying time points from baseline. Results During the first year of follow-up, 135 subjects (73%) had stable FVC while 50 subjects (37%) showed a decline in FVC. During months 12 to 24 (1-2 years after diagnosis), a stable FVC occurred with the same frequency among both subjects whose FVC had declined during year 1 and whose FVC had remained stable (84.0% and 80.7%, respectively; P = .59). Among subjects alive at the end of year 1, those with a stable FVC were more likely to be alive at the end of year 2 than those whose FVC declined (hazard ratio [HR], 0.91 [95% CI, 0.87-0.94] and HR, 0.71 [95% CI, 0.62-0.78], respectively). Conclusions PFT decline predicts early mortality, but not future declines in physiology, regardless of time since diagnosis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24231810</pmid><doi>10.1378/chest.13-0844</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0012-3692
ispartof Chest, 2014-03, Vol.145 (3), p.579-585
issn 0012-3692
1931-3543
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3941249
source MEDLINE; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Disease Progression
Female
Follow-Up Studies
Humans
Idiopathic Pulmonary Fibrosis - diagnosis
Idiopathic Pulmonary Fibrosis - mortality
Idiopathic Pulmonary Fibrosis - physiopathology
Male
Middle Aged
Original Research
Predictive Value of Tests
Prognosis
Pulmonary/Respiratory
Respiratory Function Tests
Retrospective Studies
Severity of Illness Index
Survival Rate - trends
Time Factors
United States - epidemiology
Vital Capacity - physiology
title Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A29%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predicting%20Pulmonary%20Fibrosis%20Disease%20Course%20From%20Past%20Trends%20in%20Pulmonary%20Function&rft.jtitle=Chest&rft.au=Schmidt,%20Shelley%20L.,%20MD&rft.date=2014-03-01&rft.volume=145&rft.issue=3&rft.spage=579&rft.epage=585&rft.pages=579-585&rft.issn=0012-3692&rft.eissn=1931-3543&rft_id=info:doi/10.1378/chest.13-0844&rft_dat=%3Cproquest_pubme%3E1504451663%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504451663&rft_id=info:pmid/24231810&rft_els_id=1_s2_0_S0012369215343713&rfr_iscdi=true